RARE CANCERGynecologicWHO 5th Edition Classification

Vulvar Cancer

Rare Malignancy (< 6 cases per 100,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

Cancer of the external female genitalia, most often squamous cell carcinoma. It arises by two distinct routes: an HPV-driven pathway affecting younger women, and a pathway from chronic lichen sclerosus and differentiated VIN in older women, which carries a worse prognosis. Diagnosis is frequently delayed because symptoms are attributed to thrush or menopausal change.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Vulval itching lasting beyond a few weeks in a postmenopausal woman warrants examination and biopsy, not repeat antifungals
Who It Affects

Predominantly women over 65, but rising in younger women through HPV

Annual Incidence

Approximately 2-3 per 100,000 women per year

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Persistent itching that does not respond to treatment
A lump, ulcer or wart-like growth on the vulva
A patch of skin that is white, red or darker than the surrounding skin
Pain, burning or bleeding not related to periods
Groin lumps from lymph node involvement

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

HPV 16 with p16 positivity in the younger cohortTP53 in the lichen sclerosus-associated pathway

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Wide radical local excision with an adequate margin

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Sentinel lymph node biopsy for tumours under 4 cm with a clinically negative groin

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Inguinofemoral lymphadenectomy where sentinel biopsy is not appropriate

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Adjuvant radiotherapy for close margins or nodal involvement

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Definitive chemoradiotherapy for locally advanced disease to avoid exenteration

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

6

Long-term dermatological management of lichen sclerosus to reduce recurrence

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Good when caught early. Five-year survival exceeds 85-90% for node-negative disease but falls to roughly 50% with inguinal node involvement and lower with multiple involved nodes. The dominant problem is presentation delay, not treatment failure.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Sentinel node techniques to reduce the substantial lymphoedema burden of full lymphadenectomy, immunotherapy in advanced HPV-driven disease, and HPV vaccination as primary prevention are the key developments.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Vulvar Cancer

Browse All Oncologists

Dr. Kathleen M. Schmeler

Gynecologic Oncologist

15+ yrs exp

MD Anderson

Houston, USA

Gynecologic OncologyVulvar CancerSentinel Node Dissection
Vetted DirectoryConsult Specialist

Dr. See Tho Kai Yin

Senior Gynecologic Oncologist

30+ yrs exp

KKH

Singapore, Singapore

Gynecologic OncologyVulvar CancerCombined Modality
Vetted DirectoryConsult Specialist

Prof. Lukas J. Bamberg

Gynecologic Oncologist

20+ yrs exp

Charité Berlin

Berlin, Germany

Gynecologic OncologyVulvar Reconstructive SurgeryRadical Excision
Vetted DirectoryConsult Specialist

Dr. Amita Maheshwari

Professor & Head, Gyne-Oncology

30+ yrs exp

Tata Memorial Hospital

Mumbai, India

Gynecologic OncologyVulvar CancerWomen's Cancer Center
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

rare

Cancer of Unknown Primary (CUP)

rare

Malignant Mesothelioma

rare

Retinoblastoma

rare

Ewing Sarcoma

Independent Tumor Board Review

Facing a Diagnosis of Vulvar Cancer?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult